Filing Details

Accession Number:
0000947871-17-000211
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-14 19:47:12
Reporting Period:
2017-03-10
Filing Date:
2017-03-14
Accepted Time:
2017-03-14 19:47:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1192448 Glaukos Corp GKOS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1171005 Jonathan Silverstein C/O Glaukos Corporation
26051 Merit Circle, Suite 103
Laguna Hills CA 92653
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.01 Per Share Disposition 2017-03-10 96,113 $45.98 2,008,071 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-03-10 915 $45.98 19,129 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-03-13 208,712 $45.30 1,799,359 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-03-13 1,998 $45.30 17,141 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-03-13 693 $46.13 1,798,666 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-03-13 7 $46.13 17,134 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-03-14 73,401 $44.54 1,725,265 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-03-14 699 $44.54 16,435 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $45.80 to $46.31 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $45.00 to $45.87 inclusive. Upon request, the Reporting Person undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $46.04 to $46.23 inclusive. Upon request, the Reporting Person undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $44.31 to $44.69 inclusive. Upon request, the Reporting Person undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  5. These securities are held of record by OrbiMed Private Investments III, LP ("OPI III") and may be deemed to be indirectly beneficially owned by OrbiMed Capital GP III LLC ("GP III"), OrbiMed Advisors LLC ("Advisors") and Samuel D. Isaly ("Isaly"). GP III is the sole general partner of OPI III. Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP III. By virtue of such relationships, GP III and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI III noted above. The Reporting Person is a member of Advisors.
  6. These securities are held of record by OrbiMed Associates III, LP ("Associates III") and may be deemed to be indirectly beneficially owned by Advisors and Isaly. Advisors is the sole general partner of Associates III. Isaly is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationship, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by Associates III noted above. As a result, each of Advisors and Isaly may be deemed to have beneficial ownership of the securities held by Associates III.
  7. Each of the Reporting Person, GP III, Advisors, and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.